The conference Professor K Kataoka (Department of Materials Science and Engineering, University of Tokyo, Japan) gave the keynote presentation in honor and memory of Sasha Kabanov's father, Professor Victor Kabanov . Among his many seminal contributions to macromolecular chemistry, Professor Kabanov discovered and quantitatively studied macromolecular exchange and substitution in interpolyelectrolyte complexes. These studies provided fundamental principles for developing bioimaging or drug-delivery nanoparticles through the complexation of charged polymers with oppositely charged imaging agents or drugs. Kataoka credited V Kabanov's work for inspiring him early in his career to explore the use of self-assembled polyelectrolyte complexes (PICs) for drug delivery. Kataoka then discussed one such PIC recently developed by his group. This latest PIC was formed from a diblock copolymer of poly(ethylene glycol)-poly(aspartate) with an ethylenediamine side chain (PEG-PAsp[DET]) and was used to successfully transfect a variety of primary cells with plasmid DNA. Kataoka also described studies where hypovascular and subsequently difficult-to-treat cancers, such as pancreatic cancer, were effectively treated by coinjecting a transforming growth factor (TGF)-β inhibitor with drugloaded polymeric complexes. This increased intratumor perfusion and consequently enhanced nanoparticle penetration into the tumor for 24 h, but had no effect on free drug. Strong antitumor and antimetastatic effects were also observed.
Professor K Uhrich (Rutgers University, NJ, USA) discussed using micelles composed of amphiphilic scorpion-like macromolecules (AScMs) to prevent the uptake of oxidized low-density lipoproteins (LDLs) by macrophages and slow the progression of atherosclerosis. AScMs possess a hydrophobic region composed of highly branched alkyl chains and a hydrophilic region composed of linear PEG chains. Uhrich found that the presence of carboxylic acids on the PEG chain ends increased the aggregation of AScMs with LDLs and preferentially blocked macrophage uptake of highly oxidized LDLs. The possible concentrationdependent formation of pulmonary emboli after systemic administration was undetermined, however, and remains a major concern.
A Jones (Cardiff University, UK) discussed the intracellular trafficking of cell-penetrating peptides, such as HIVtransactivating transcriptional activator (TAT) and octaargine, in sensitive and drug-resistant immortalized cells. He observed that, unlike drug-sensitive cells, drug-resistant cells traffic peptides exclusively to the lysosomes. Furthermore, endocytosis of these peptides at low concentrations was inhibited at 4°C (energy-dependent endocytosis is inhibited), whereas a diffuse cytosolic pattern of peptide was observed at high concentrations. It remained undetermined, however, whether the surface activity of either peptide at high concentrations solubilizes the plasma membrane at 4°C to allow peptide entry.
J Hanes (Johns Hopkins University, MA, USA) compared the real time intracellular trafficking of synthetic drug-delivery nanoparticles with adenovirus using quantitative confocal nanoparticle tracking. Like others, he observed rapid perinuclear accumulation of a subset of both nanoparticles and adenovirus in the lysosomes within approximately 1 h and, unlike adenovirus, the majority of nanoparticles were unable to escape the lysosomes. He also observed that nanoparticle PEGylation increased the extent of endosomal trafficking and that nanoparticles appear to primarily escape the endosomes during endosomal sorting.
V Torchilin (Northeastern University, MA, USA) discussed a 'double targeted' PEGylated liposome he recently developed for cancer therapy to improve both extracellular and intracellular drug targeting. The nanocarrier was composed of PEGylated phospholipids having nucleosome-specific 2C5
For reprint orders, please contact: reprints@futuremedicine.com antibodies attached to the ends of pH-sensitive PEG chains. The 2C5 antibody binds to nucleosomes found only on the surface of cancer cells to improve tumor targeting. The nanocarrier also contained surface-bound TAT peptides that are physically covered by the PEG chains. Upon endocytosis, the pH-sensitive PEG chains are released in the low pH environment of the endosomes, exposing the TAT peptides to facilitate endosomal release. Increased accumulation and antitumor activity in vivo were observed.
H Gendelman UNMC discussed using bone marrow macrophages (BMM), as cell-based drug carriers to improve the bioavailability and pharmacokinetics of nanoformulated antiretroviral drugs, such as indavir (IDV). The adoptive transfer (injection) of BMMs loaded with nanoformulated IDV increased IDV plasma levels above its effective dose (ED 50 ) and the tissue distribution of IDV delivered by IDV-loaded BMMs paralleled the distribution of BMMs. Survival of CD4+ T cells and antiretroviral activity in a humanized mouse model of HIV infection were also increased over untreated controls.
C Glabe (University of California, Irvine, CA, USA) discussed approaches to target amyloid oligomers for the treatment of neurodegenerative diseases. Antibodies were generated against three distinct sequences (prefibrillar oligomers, pore-like annular protofibrils and amyloid fibrils). These antibodies recognized the three β-structures in many different types of amyloids, indicating that a general structural motif responsible for toxicity may be common to all amyloid proteins. Glabe also observed that only the soluble, prefibrillar oligomers from all types of amyloidogenic proteins possessed membrane permeabilizing activity and that this may be the primary mechanism of amyloid pathogenesis. Thus, nanomedicine approaches that block amyloid pore formation by soluble prefibrillar oligomers may be effective in the treatment of a wide range of neurodegenerative diseases. M Porter (Arizona State University, AZ, USA) discussed ultralow level detection and diagnosis of diseases using assays based on surface-enhanced Raman spectroscopy (SERS). Porter developed an assay similar to a sandwich enzyme-linked immunosorbent assay (ELISA), where alkylthiolated antibodies recognizing one region of an antigen were coupled to a gold film surface, and an extrinsic Raman label (homogeneously sized gold nanoparticles covered with alkylthiolated antibodies that recognize a different region of the antigen) was used to detect the captured antigen. This approach also allows for simultaneous detection of multiple antigens (multiplexing) by adding an appropriate pair of capture and detection antibodies and unique diameter of the gold nanoparticle for each additional antigen. Evidence of the high level of sensitivity and robustness provided by the SERS sandwich assay was demonstrated with prostate-specific antigen (PSA), where a limit of detection of 30 fM was observed in human serum.
R Prud'homme (Princeton University, NJ, USA) described a novel, scalable process called 'flash nanoprecipitation' for nanoparticle production. The process involves forming nanosized drug aggregates over very short time scales, then stabilizing the aggregates with biocompatible amphiphilic block copolymers containing PEG. Nanoparticle size is controlled by mixing intensity, degree of supersaturation and rate of drug nucleation. The process produces nanoparticles with high levels of drug loading that can be lyophilized and reconstituted without aggregation and are flexible enough to allow for the development of an almost unlimited number of applications.
F Ledley (Bentley College, MA, USA), cofounder of Genemedicine Inc., outlined a number of the lessons he learned in attempting to bring a therapy from the bench to the bedside. The need to choose a delivery technology capable of clinical success, perform achievable clinical trials before full-scale development and balance the role of academics, companies, investors and partners during the process were the major messages of his discussion.
A Polinsky (V.P. Global Technologies, Pfizer), a former graduate student of V Kabanov, discussed the current gap between academic and industrial development of nanomedicine technologies. Polinsky proposed that this gap is driven by the "wait and see" attitude of big Pharma, which produces a "Big business model gap". According to this model, start-up companies will fill in the gap to provide industrial nanomedicine applications that are either licensed or acquired through the purchase of start-ups by big Pharma. Polinsky predicted that the gap will narrow significantly in the next 5 years, but suggested that academia could help close the gap earlier by considering the same practical aspects of nanomedicine applications that must be considered by big Pharma.
B Rabinow (Baxter) discussed Baxter's NANOEDGE technology that increases the solubility of poorly water-soluble drugs. The process involves physically homogenizing larger crystals of pure drug into 200-400 nm nanoparticles. Increased oral bioavailability is observed with decreasing particle size, and extended intravenous release and lower toxicity are also observed compared with solubilized, free drug alone.
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Highlights
• Coinjection of transforming growth factor-β inhibitors with drug-loaded polymeric complexes increases nanoparticle penetration into tumors and subsequent antitumor and antimetastatic activity.
• Conventional drug-delivery nanoparticles appear to primarily escape the endosomes during endosomal sorting.
• Nanomedicine approaches that block the formation of amyloid pores by soluble prefibrillar oligomers may be effective in the treatment of a wide range of neurodegenerative diseases.
• Cell-based delivery of nanoformulated antiretroviral drugs using bone marrow macrophages improves drug bioavailability, toxicity profile and pharmacokinetics.
• Ultralow level detection (e.g., 30 fM prostate-specific antigen in human serum) can be achieved using a surface-enhanced Raman spectroscopy based assay similar to sandwich enzyme-linked immunosorbent assay.
• 'Flash nanoprecipitation' is a novel, scalable method for producing stable nanoparticles with unusually high levels of drug loading that has great potential for developing unique drug and bioimaging nanoparticles.
• The gap in industrial nanomedicine applications between academia and industry is predicted to narrow significantly within the next 5 years, but academic consideration of the same practical aspects considered by big Pharma could increase the rate of gap closure.
